JP2020534370A - 神経芽腫の治療のための抗ｇｄ２抗体 - Google Patents

神経芽腫の治療のための抗ｇｄ２抗体 Download PDF

Info

Publication number
JP2020534370A
JP2020534370A JP2020538517A JP2020538517A JP2020534370A JP 2020534370 A JP2020534370 A JP 2020534370A JP 2020538517 A JP2020538517 A JP 2020538517A JP 2020538517 A JP2020538517 A JP 2020538517A JP 2020534370 A JP2020534370 A JP 2020534370A
Authority
JP
Japan
Prior art keywords
antibody
fragment
iga
chain variable
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020538517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534370A5 (https=
Inventor
ヘンリカ ウィルヘルミナ ルーセン，ヤネット
ヘンリカ ウィルヘルミナ ルーセン，ヤネット
ヨハネス ヘラルデス マリア エーヴァス，
ヨハネス ヘラルデス マリア エーヴァス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
Original Assignee
UMC Utrecht Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV filed Critical UMC Utrecht Holding BV
Publication of JP2020534370A publication Critical patent/JP2020534370A/ja
Publication of JP2020534370A5 publication Critical patent/JP2020534370A5/ja
Priority to JP2023189702A priority Critical patent/JP2024023238A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2020538517A 2017-09-21 2018-09-21 神経芽腫の治療のための抗ｇｄ２抗体 Pending JP2020534370A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023189702A JP2024023238A (ja) 2017-09-21 2023-11-06 神経芽腫の治療のための抗ｇｄ２抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192476.4 2017-09-21
EP17192476 2017-09-21
PCT/NL2018/050629 WO2019059771A2 (en) 2017-09-21 2018-09-21 ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023189702A Division JP2024023238A (ja) 2017-09-21 2023-11-06 神経芽腫の治療のための抗ｇｄ２抗体

Publications (2)

Publication Number Publication Date
JP2020534370A true JP2020534370A (ja) 2020-11-26
JP2020534370A5 JP2020534370A5 (https=) 2021-11-04

Family

ID=59955406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020538517A Pending JP2020534370A (ja) 2017-09-21 2018-09-21 神経芽腫の治療のための抗ｇｄ２抗体
JP2023189702A Pending JP2024023238A (ja) 2017-09-21 2023-11-06 神経芽腫の治療のための抗ｇｄ２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023189702A Pending JP2024023238A (ja) 2017-09-21 2023-11-06 神経芽腫の治療のための抗ｇｄ２抗体

Country Status (12)

Country Link
US (2) US11866511B2 (https=)
EP (1) EP3684818A2 (https=)
JP (2) JP2020534370A (https=)
KR (1) KR20200059249A (https=)
CN (1) CN111278862A (https=)
AU (3) AU2018336017B2 (https=)
BR (1) BR112020005742A2 (https=)
CA (1) CA3076482A1 (https=)
IL (1) IL273454A (https=)
MX (1) MX2020003201A (https=)
SG (1) SG11202002581WA (https=)
WO (1) WO2019059771A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN111849904B (zh) * 2020-07-31 2021-05-04 浙江科途医学科技有限公司 神经母细胞瘤类器官的培养基、培养方法及移植体
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539122A (ja) * 2013-11-21 2016-12-15 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ Ｇｄ２陽性がんを処置するための製剤および方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP1916257A1 (en) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
EP2578681B1 (en) 2010-05-24 2015-07-01 Kagoshima University Iga-binding peptide and iga purification using same
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
CN106414494B (zh) * 2013-11-12 2020-09-18 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体
CN105732814B (zh) * 2016-03-08 2019-05-28 苏州大学 抗人血管性血友病因子a3区的人鼠嵌合单克隆抗体及其制备方法和应用
EP3747438A1 (en) 2017-07-24 2020-12-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539122A (ja) * 2013-11-21 2016-12-15 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ Ｇｄ２陽性がんを処置するための製剤および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 76, no. 2, JPN6022036494, 2016, pages 403 - 417, ISSN: 0005272433 *

Also Published As

Publication number Publication date
AU2018336017B2 (en) 2021-06-24
US20210179732A1 (en) 2021-06-17
KR20200059249A (ko) 2020-05-28
BR112020005742A2 (pt) 2020-10-13
US20200283541A1 (en) 2020-09-10
CN111278862A (zh) 2020-06-12
AU2025201363A1 (en) 2025-03-20
EP3684818A2 (en) 2020-07-29
SG11202002581WA (en) 2020-04-29
MX2020003201A (es) 2020-08-13
AU2021236513A1 (en) 2021-10-21
CA3076482A1 (en) 2019-03-28
JP2024023238A (ja) 2024-02-21
WO2019059771A3 (en) 2019-10-10
US11866511B2 (en) 2024-01-09
NZ762835A (en) 2024-12-20
IL273454A (en) 2020-05-31
WO2019059771A2 (en) 2019-03-28
AU2018336017A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11866511B2 (en) Anti-GD2 antibody
US20250179189A1 (en) Anti-SIRPa Antibodies and Methods of Use Thereof
JP7455787B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
CN110392694B (zh) 针对pd-1的抗体及其用途
JP6816038B2 (ja) 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
JP6707531B2 (ja) 抗ｃｄ３８抗体による併用療法
TW202204388A (zh) 經遮蔽之il-2細胞激素及其裂解產物
IL301956A (en) Antibodies against dectin-1 and methods of using them
JP2018502834A (ja) 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
JP2021513329A (ja) 抗ｍｓ４ａ４ａ抗体及びその使用方法
EP3816290A1 (en) Antibody binding to cell adhesion molecule 3
JP7490923B2 (ja) 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
JP6219923B2 (ja) Ｄｒ５受容体アゴニストの組み合わせ
KR20160126027A (ko) 급성 림프아구성 백혈병을 치료하기 위한 항-cd38 항체
US20230235055A1 (en) Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
EA036927B1 (ru) Конъюгированные антитела против ly75 для лечения рака
EP3816291B1 (en) ANTIBODIES BINDING TO PROTEOGLYCAN-5 WITH CHONDROITINE SULFATE
CN112512638A (zh) 抗siglec-7抗体及其使用方法
KR102058185B1 (ko) Adp-리보실 시클라제 2에 대한 항체
RU2798246C2 (ru) Биспецифические антитела против ceacam5 и cd47
CN111132697A (zh) 包含抗bst-1抗体和胞苷类似物的药物组合
TWI724046B (zh) 以抗ｃｄ３８抗體與生存素抑制劑於血紅素惡性腫瘤之組合治療
HK40104849A (zh) 用於诊断和治疗用途的针对lilrb1的单克隆抗体
HK40047633A (en) Anti-siglec-7 antibodies and methods of use thereof
HK40030237A (en) Anti-sirp-alpha antibodies and related methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221209

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231218

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240301